Colonic sarcoidosis, infliximab, and tuberculosis: A cautionary tale

Inflammatory Bowel Diseases

Volumn 10, Issue 4, 2004, Pages 438-440

  Sorrentino, Dario ^a,b   Avellini, Claudio ^a   Zearo, Ester ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

Author keywords

Colonic sarcoidosis; Infliximab; Intestinal tuberculosis

Indexed keywords

CYCLOSPORIN; INFLIXIMAB; PREDNISONE;

ABDOMINAL PAIN; ADULT; ARTICLE; CARCINOMATOUS PERITONITIS; CASE REPORT; COLON BIOPSY; COLON DISEASE; COLON MUCOSA; DIAGNOSTIC ERROR; DISEASE DURATION; FEMALE; FEVER; GRANULOMA; HUMAN; INTESTINE TUBERCULOSIS; MILIARY TUBERCULOSIS; MUSCLE WEAKNESS; PRIORITY JOURNAL; SARCOIDOSIS; SYSTEMIC DISEASE; WELLBEING;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; COLONIC DISEASES; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC ERRORS; FATAL OUTCOME; FEMALE; GRANULOMA; HUMANS; MIDDLE AGED; SARCOIDOSIS; TUBERCULOSIS, GASTROINTESTINAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3543064738     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200407000-00018     Document Type: Article

References (18)

1. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344:1105-1110.
2. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997; 337:1029-1035.
3. Su C, Lichtenstein GR. Recent developments in inflammatory bowel disease. Med Clin North Am. 2002;86:1497-1523.
4. Yee AMF, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor - α therapy. Ann Intern Med. 2001; 135:27-31.
5. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med. 1997;336: 1224-1234.
6. Dumot JA, Adal K, Petras RE, et al. Sarcoidosis presenting as granulomatous colitis. Am J Gastroenterol. 1998;93:1949-1951.
7. Pettersen JA, Zochodne DW, Bell RB, et al. Refractory neurosarcoidosis responding to infliximab. Neurology. 2002;59:1660-1661.
8. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098-1104.
9. Bean AG, Roach DR, Briscoe H. et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol. 1999;162:3504-3511.
10. Bulger K. O'Riordan M. Purdy S. et al. Gastrointestinal sarcoidosis resembling Crohn's disease. Am J Gastroenterol. 1988;83:1415-1417.
11. Horvath KD, Whelan RL. Intestinal tuberculosis: return of an old disease. Am J Gastroenterol. 1998;93:692-696.
12. Hilzenrat N, Spanier A, Lamoureux E, et al. Colonic obstruction secondary to sarcoidosis: nonsurgical diagnosis and management. Gastroenterology. 1995;108:1556-1559.
13. Serio RN. Inflixamb treatment of sarcoidosis. Ann Pharmacother. 2003; 37:577-581.
14. Abraham LJ, French MA, Dawkins RL. Polymorphic MHC ancestral haplotypes affect the activity of tumor necrosis factor-alpha. Clin Exp Immunol. 1993;92:14-18.
15. De Rosa FG, Bonora S, Di Perri G. Tuberculosis and treatment with infliximab. N Engl J Med. 2002;346:623-626.
16. Wagner TE, Huseby ES, Huseby JS. Exacerbation of Mycobacterium tuberculosis enteritis masquerading as Crohn's disease after treatment with a tumor necrosis factor-alpha inhibitor. Am J Med. 2002;112:67-69.
17. Taylor JC, Orkin R, Lanham J. Tuberculosis following therapy with infliximab may be refractory to antibiotic therapy. Rheumatology. 2003;42: 901-902.
18. O'Connor TM, Shanahan F, Bredin CP. Infliximab therapy for complicated sarcoidosis. Ann Intern Med. 2002;137:296-297.